Embla Medical hf Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Embla Medical hf ha aumentado sus beneficios a una tasa media anual de 6%, mientras que los beneficios de la industria de Medical Equipment han experimentado un crecimiento de 9.7% anual. Los ingresos han ido creciendo a una tasa media de 4.9% al año. La rentabilidad financiera de Embla Medical hf es de 8.8%, y sus márgenes netos son de 8.2%.

Información clave

6.0%

Tasa de crecimiento de los beneficios

5.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Medical Equipment	-1.7%
Tasa de crecimiento de los ingresos	4.9%
Rentabilidad financiera	8.8%
Margen neto	8.2%
Próxima actualización de resultados	05 Feb 2025

Actualizaciones de resultados anteriores recientes

Recent updates

Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 25

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Jul 26

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Jul 17

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

May 14

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 26

A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Apr 10

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Mar 23

Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Jan 21

Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Jan 03

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Nov 28

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Nov 08

A Look At The Fair Value Of Össur hf. (CPH:OSSR)

Sep 23

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Aug 21

Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Jul 18

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Jun 14

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

May 19

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Mar 14

A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

Jan 21

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

Dec 22

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Dec 07

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Sep 21

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Sep 02

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Aug 16

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Jun 16

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Jun 01

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

May 08

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Feb 22

Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report

Feb 03

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Nov 25

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Oct 17

Is Össur hf (CPH:OSSR) A Risky Investment?

Sep 28

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

Aug 21

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Jul 11

Here's Why Össur hf (CPH:OSSR) Can Manage Its Debt Responsibly

May 28

Calculating The Fair Value Of Össur hf. (CPH:OSSR)

May 07

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Mar 25

We Think The Compensation For Össur hf.'s (CPH:OSSR) CEO Looks About Right

Mar 02

We Think Össur hf (CPH:OSSR) Can Stay On Top Of Its Debt

Feb 22

Does The Market Have A Low Tolerance For Össur hf.'s (CPH:OSSR) Mixed Fundamentals?

Feb 09

Desglose de ingresos y gastos

Cómo gana y gasta dinero Embla Medical hf. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

CPSE:EMBLA Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 24	840	69	375	40
30 Jun 24	820	61	371	39
31 Mar 24	804	57	368	38
31 Dec 23	786	58	360	38
30 Sep 23	766	52	353	37
30 Jun 23	750	45	354	36
31 Mar 23	730	43	345	34
31 Dec 22	719	43	339	34
30 Sep 22	715	47	339	34
30 Jun 22	719	57	331	33
31 Mar 22	728	62	331	34
31 Dec 21	719	64	328	32
30 Sep 21	701	50	323	32
30 Jun 21	692	48	318	31
31 Mar 21	637	11	308	31
31 Dec 20	630	6	307	31
30 Sep 20	639	20	303	30
30 Jun 20	635	19	308	30
31 Mar 20	680	59	311	31
31 Dec 19	686	66	308	31
30 Sep 19	675	83	296	31
30 Jun 19	652	85	284	31
31 Mar 19	631	83	274	31
31 Dec 18	613	80	265	31
30 Sep 18	599	69	259	31
30 Jun 18	593	64	254	31
31 Mar 18	579	58	252	30
31 Dec 17	569	58	245	29
30 Sep 17	553	49	246	29
30 Jun 17	543	51	239	27
31 Mar 17	538	52	240	25
31 Dec 16	521	51	233	23
30 Sep 16	507	49	227	21
30 Jun 16	495	50	219	20
31 Mar 16	483	51	209	19
31 Dec 15	483	51	208	18
30 Sep 15	488	54	209	18
30 Jun 15	497	55	213	18
31 Mar 15	502	57	214	19
31 Dec 14	509	59	218	19
30 Sep 14	509	58	217	20
30 Jun 14	487	55	207	20
31 Mar 14	460	46	199	21
31 Dec 13	436	40	189	22

Ingresos de calidad: EMBLA tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (8.2%) de EMBLA son superiores a los del año pasado (6.8%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de EMBLA han crecido un 6% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de EMBLA en el último año (32.1%) supera su media de 5 años (6% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de EMBLA en el último año (32.1%) superó al de la industria Medical Equipment 13%.

Embla Medical hf Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

Full year 2023 earnings: EPS misses analyst expectations

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Third quarter 2023 earnings released: EPS: US$0.033 (vs US$0.016 in 3Q 2022)

Recent updates

Results: Embla Medical hf. Beat Earnings Expectations And Analysts Now Have New Forecasts

Third quarter 2024 earnings released: EPS: US$0.051 (vs US$0.033 in 3Q 2023)

Estimating The Intrinsic Value Of Embla Medical hf. (CPH:EMBLA)

Now 21% undervalued

Do Embla Medical hf's (CPH:EMBLA) Earnings Warrant Your Attention?

Embla Medical hf.'s (CPH:EMBLA) Share Price Matching Investor Opinion

Earnings Beat: Embla Medical hf. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Embla Medical hf. Revises Earnings Guidance for the Full Year of 2024

Calculating The Fair Value Of Embla Medical hf. (CPH:EMBLA)

Market Participants Recognise Embla Medical hf.'s (CPH:EMBLA) Earnings

Embla Medical hf. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

First quarter 2024 earnings released: EPS: US$0.019 (vs US$0.024 in 1Q 2023)

New minor risk - Financial position

A Look At The Fair Value Of Embla Medical hf. (CPH:OSSR)

Is Össur hf (CPH:OSSR) Using Too Much Debt?

Össur hf. Appoints Caroline Vagner Rosenstand to the Audit Committee

Investor sentiment improves as stock rises 15%

Full year 2023 earnings: EPS misses analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2024

Why Investors Shouldn't Be Surprised By Össur hf.'s (CPH:OSSR) P/E

Calculating The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2024 Results on Apr 23, 2024

Össur hf., Annual General Meeting, Mar 12, 2025

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Third quarter 2023 earnings released: EPS: US$0.033 (vs US$0.016 in 3Q 2022)

Össur hf. Reaffirms Financial Guidance for the Year 2023

A Look At The Fair Value Of Össur hf. (CPH:OSSR)

We Think Össur hf (CPH:OSSR) Is Taking Some Risk With Its Debt

Second quarter 2023 earnings: EPS misses analyst expectations

Össur hf (CPH:OSSR) May Have Issues Allocating Its Capital

Össur hf. Announces Executive Changes

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 19% Below Its Share Price

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

First quarter 2023 earnings released: EPS: US$0.024 (vs US$0.022 in 1Q 2022)

Össur hf (CPH:OSSR) Might Be Having Difficulty Using Its Capital Effectively

Consensus EPS estimates fall by 12%

Full year 2022 earnings: Revenues in line with analyst expectations

Össur hf. Provides Earnings Guidance for the Year 2023

A Look At The Intrinsic Value Of Össur hf. (CPH:OSSR)

Össur hf. to Report Q1, 2023 Results on Apr 25, 2023

These 4 Measures Indicate That Össur hf (CPH:OSSR) Is Using Debt Reasonably Well

There Are Reasons To Feel Uneasy About Össur hf's (CPH:OSSR) Returns On Capital

Less than half of directors are independent

Consensus EPS estimates fall by 23%

Third quarter 2022 earnings released: EPS: US$0.016 (vs US$0.041 in 3Q 2021)

Investor sentiment improved over the past week

Are Investors Undervaluing Össur hf. (CPH:OSSR) By 37%?

Returns On Capital Signal Tricky Times Ahead For Össur hf (CPH:OSSR)

Össur hf. (CPSE:OSSR) acquired Naked Prosthetics.

Össur hf (CPH:OSSR) Seems To Use Debt Quite Sensibly

Second quarter 2022 earnings released: EPS: US$0.034 (vs US$0.046 in 2Q 2021)

Price target decreased to kr.42.00

Össur hf. Revises Earnings Guidance for the Year 2022

Össur hf. Reports Preliminary Earnings Results for the Second Quarter and First Half of 2022

Össur Appoints Gudny Arna Sveinsdottir as Chief Financial Officer, Effective September 1, 2022

Price target decreased to kr.43.70

Össur hf.'s (CPH:OSSR) Intrinsic Value Is Potentially 42% Above Its Share Price

Now 22% undervalued after recent price drop

Össur hf (CPH:OSSR) Will Want To Turn Around Its Return Trends

Does Össur hf (CPH:OSSR) Have A Healthy Balance Sheet?

Now 20% undervalued after recent price drop

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Össur Hf. Announces New R&D Leadership

Össur hf (CPH:OSSR) Will Be Hoping To Turn Its Returns On Capital Around

Össur Launches New POWER KNEE

Analysts Have Made A Financial Statement On Össur hf.'s (CPH:OSSR) Yearly Report